Atul Humar, MD, MSc, FRCPC, FAST

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Takeda
    Topic:
    CMV
    Date added:
    10/10/2026
    Date updated:
    10/11/2026
    Relationship end date:
    03/01/2026
  • Attribution:
    Self
    Type of financial relationship:
    Consultant
    Ineligible company:
    Merck
    Topic:
    CMV
    Date added:
    10/11/2026
    Date updated:
    10/11/2026
    Relationship end date:
    03/01/2026
  • Attribution:
    Self
    Type of financial relationship:
    Researcher
    Ineligible company:
    Takeda, Synklino
    Topic:
    CMV
    Date added:
    10/11/2026
    Date updated:
    10/11/2026
  • Attribution:
    Self
    Type of financial relationship:
    Speaker
    Ineligible company:
    Eurofins
    Topic:
    CMV
    Date added:
    10/11/2026
    Date updated:
    10/11/2026
    Relationship end date:
    03/01/2026
  • Attribution:
    Self
    Type of financial relationship:
    Speaker
    Ineligible company:
    Takeda
    Topic:
    CMV
    Date added:
    10/11/2026
    Date updated:
    10/11/2026
    Relationship end date:
    03/01/2026
  • Attribution:
    Self
    Type of financial relationship:
    Speaker
    Ineligible company:
    Kamada
    Topic:
    CMV
    Date added:
    10/11/2026
    Date updated:
    10/11/2026
    Relationship end date:
    03/01/2026
Return to Navigating Modern CMV Antivirals: Applying Guideline Updates to Clinical Practice